explored in depth in the in the body of the article. Transcatheter valve therapy in the emerging environment of the hybrid operating room (OR) will likely disseminate even more globally, as further approvals from regulating agencies are obtained in new countries and for new devices. The venue for these breakthrough technologies will likely increasingly be the hybrid OR, best understood as merging the advantages of the cardiac catheterization laboratory and the operating room. This new perioperative venue will continue to facilitate novel interventions as specialists embrace the unfolding endovascular revolution in cardiovascular medicine. Perioperative myocardial conditioning of the myocardium has gained increasing attention as trials consistently demonstrate enhancement of clinical outcomes after cardiac surgery with exposure to volatile anesthetics, levosimendan and ischemia, both local and remote. It is likely that these perioperative techniques will gradually be integrated into the conduct of cardiothoracic and vascular procedures, as the outcome advantages are demonstrated in adequately powered trials with meaningful clinical end-points. In contrast, perioperative exposure to angiotensin blockade and anemia independently predict adverse outcome after coronary artery bypass grafting (CABG). The outcome advantages of off-pump CABG appear to be confined to high-risk patients. Endoscopic saphenous vein harvesting may increase the risks of coronary graft thrombosis to worsen clinical outcomes after CABG. In contrast, the aggressive management of ST-elevation myocardial infarction (STEMI) with percutaneous coronary intervention (PCI) consistently improves outcomes across multiple trials. The indications for intraaortic balloon counterpulsation in STEMI have recently been questioned as the outcome advantages are not substantial in recent trials. Although prasugrel appears likely to replace clopidogrel, the future of oral thienopyridine platelet blockade may be moving to direct and reversible blockade with ticagrelor, pending the results of large trials currently in progress. With these advances in platelet blockade, the role of PCI may continue to expand in the management of multivessel coronary artery disease (CAD). Although PCI appears equivalent to CABG for multivessel CAD in select groups, it still has a significantly higher risk of revascularization and adverse outcomes in diabetics and patients >65 years old. It is likely that the interventional management of CAD will be integrated in the hybrid OR in the future search for the best combined approach to CAD. Since bleeding and transfusion after cardiac surgery independently predict adverse outcome, the impaired hemostasis associated with hetastarch and N-acetylcysteine is concerning. The perioperative safety of factor VII in severe bleeding requires further study. The advent of the thrombopoeitin agonists such as eltrombopag and romiplostim offers the opportunity to boost preoperative platelet levels which may have a clinical niche in the cardiac surgical patient. Similarly to bleeding and transfusion, renal dysfunction independently predicts adverse outcome after cardiac surgery. Pilot data suggest that fenoldopam, atrial natriuretic peptide and sodium bicarbonate may be nephroprotective after cardiac surgery. Although further trials are indicated to explore their efficacy and safety, the search for nephroprotective agents in our specialty is a priority, given the outcome importance of maintaining renal function perioperatively. In a similar fashion, ongoing trials have explored the safety and efficacy of perioperative glucose management. Although goal glucose level ≤180 mg/dL enhance clinical outcome after adult cardiac surgery, these outcome advantages are not universal. Tighter glucose control for levels in the range of 80-110 mg/dL not only does not offer any clinical advantage but substantially increases the risk of hypoglycemia.
TRAnSCATHETER VALVE InTERVEnTIonS

Aortic valve
Transcatheter aortic valve implantation (TC AVI) is a major innovation in our specialty and consequently has received considerable attention (1-4). This technology will generalize further in the USA if the landmark PARTNER trial (Placement of AoRTic TraNscathetER Valve Trial: full details available at www.clinicaltrials. gov, last accessed March 2 nd 2010) demonstrates significant outcome improvement. It is essential that the anesthesia team thoroughly understands the entire TC AVI procedure as their focused and integrated participation is essential for the success of this challenging procedure, including transesophageal echocardiography (TEE) (5-8). The major phases in the conduct of TC AVI each have their complications (9) (10) (11) . Vascular access may be complicated by arterial rupture, apical tearing, and aortic dissection. Malsizing of the aortic prosthesis may be complicated by valve embolization, aortic annulus rupture and aortic dissection. Errors in rapid transvenous ventricular pacing may allow ventricular ejection to interfere with balloon valvuloplasty and subsequent valve deployment. Errors in aortic prosthesis positioning may be complicated by valve prolapse, valve embolization, coronary occlusion as well as rupture of the aortic root and left ventricular outflow tract. The successful management of complications depends on rapid and effective multidisciplinary teamwork in the hybrid OR setting (9-13). The hybrid OR will likely also significantly impact the interventional management of CAD (14) . A recent trial (N=366) demonstrated that completion angiography after CABG in a hybrid OR allowed diagnosis of graft inadequacies in 12% of cases. These lesions were all corrected there and then in the hybrid OR with either PCI or surgical revision. The hybrid OR has brought advanced fluoroscopy to the intraoperative management of CAD with significant effect. This is analogous to the effect of TEE on the conduct of cardiac surgery, where the ability to image the structures of interest and receive immediate feedback has fundamentally altered our specialty forever (15, 16) .
Mitral valve
Transcatheter mitral valve therapy has recently progressed far beyond balloon valvuloplasty for mitral stensosis and these many of the novel therapies are currently in clinical trials (17) (18) (19) . Transcatheter Alfieri mitral valve repair is now possible with an array of technologies that enable leaflet edge-to-edge union. Percutaneous mitral annuloplasty is also possible through stenting of the coronary sinus that is closely related to the mitral annulus. It is likely that these 2 therapeutic approaches may be combined in the future to significantly enhance the durability of the repair, as evidenced by the surgical approach (20) . Furthermore, the hybrid operating room will likely become their natural venue as cardiothoracic surgeons master these innovative approaches that have established their safety and efficacy in clinical trials (21) . Indeed, it is logical that dual transcatheter aortic and mitral valve interventions will be possible in the near future once the individual technologies have entered clinical practice. 
HSR Proceedings in
PERIoPERATIVE CondITIonInG FoR MYoCARdIAL PRoTECTIon
Volatile anesthesia
Volatile anesthetics have been demonstrated to condition the myocardium protectively to better tolerate ischemia-reperfusion (22, 23) . The outcome importance of this important characteristic of our volatile anesthetics was investigated in a massive multicenter Italian CABG cohort study (N=34 310: 64 centers) (24) . Exposure to volatile anesthesia significantly lowered perioperative mortality (P=0.035), especially if there was prolonged duration (P=0.022) or if the volatile agent was isoflurane (P=0.039). These positive findings add more weight to the argument that the contemporary cardiac anesthetic should include a volatile component for optimal outcome (25) .
Levosimendan
Levosimendan is a calcium-sensitizing inodilator that may exert beneficial outcome effects when administered as soon as possible after anesthetic induction, including reduced troponin release (P=0.0003) and hospital stay (P=0.05) (26, 27) . A recent meta-analysis (cumulative N=440: 10 trials) confirmed that levosimendan exposure significantly reduced mortality after cardiac surgery (odds ratio 0.35; 95% confidence interval 0.18-0.71; P=0.003) (28) . These encouraging observations have spawned multiple clinical randomized trials across both in adult and pediatric heart surgery to more fully explore perioperative benefits due to levosimendan (full details available at www.clinicaltrials.gov, last accessed March 17 th 2010).
Ischemic conditioning
Although ischemic preconditioning confers significant ischemic tolerance to the myocardium, its perioperative application has mostly been evaluated in small trials. Recent meta-analysis (cumulative N=933: 22 trials) confirmed its outcome benefits after cardiac surgery: protection against ventricular arrhythmias (odds ratio 0.11; 95% confidence intervals 0.04-0.29; P=0.001) and inotrope sparing (odds ratio 0.34; 95% confidence interval 0.17-0.68; P=0.002) (29) . Given the cumulative benefits of this intervention, its perioperative safety and efficacy should be further evaluated in adequately powered clinical trials (29, 30) .
Remote ischemic conditioning
Remote ischemic preconditioning is defined as ischemic myocardial protection following brief ischemia of a remote tissue and has mainly been studied in small clinical trials (31 
SuRGICAL MAnAGEMEnT oF CoRonARY ARTERY dISEASE
The dangers of perioperative angiotensin blockade Angiotensin-converting enzyme inhibitor (ACEI) therapy has already been highlighted as an independent predictor for significant perioperative hypotension (37) (38) (39) 
Intra-aortic balloon pump therapy in myocardial infarction
Although intra-aortic balloon counterpulsation (IABP) has been recommended for STEMI with cardiogenic shock, the evidence supporting this recommendation was examined in a recent meta-analysis (60) . In the analysis of 7 randomized trials (N=1.009), IABP did not improve outcome, and significantly increased stroke and bleeding. In the analysis of 9 observational studies (N=10.529), IABP only decreased mortality in STEMI managed with primary fibrinolysis (95% confidence interval 16%-20%; P<0.0001). The evidence supporting IABP in STEMI is weak at best.
The new platelet blockers prasugrel and ticagrelor
Prasugrel is a novel thienopyridine that blocks platelets more reliably than clopdogrel. Both these agents block the adenosine diphosphate P 2 Y 12 receptor and both requires biotransformation in the liver to form the active drug metabolites (61) . In acute coronary syndromes, prasugrel was superior to clopidogrel for ischemic reduction (hazard ratio 0.81i; 95% confidence interval 0.73-0.90; P<0.001), but at the expense of bleeding risk (hazard ratio 1.32; 95% confidence interval 1.03-1.68; P=0.03) (62) . A multicenter global randomized trial (N=3534) also demonstrated the superiority of prasugrel over clopidogrel in STEMI, based on the composite endpoint of cardiovascular death, MI or stroke (hazard ratio 0.68; 95% confidence interval 0.54-0.87; P=0.0017) (63) . An important perioperative observation from this trial was that prasugrel significantly increased bleeding after CABG (P=0.0033). The thienopyridines, clopidogrel and prasugrel, bind irreversibly to the platelet ADP P 2 Y 12 receptor after hepatic biotransformation and are therefore indirect irreversible platelet inhibitors (64) . The novel thienopyridine, ticagrelor, binds directly to the platelet ADP P2Y 12 receptor and requires no hepatic activation (64) . In acute coronary syndromes (N=18.624), ticagrelor was superior to clopidogrel, based on the composite endpoint of cardiovascular death, MI or stroke (hazard ration 0.84; 95% confidence interval 0.77-0.92; P<0.001) (65 
